Stromal vascular fraction (SVF) has emerged as a versatile autologous therapeutic strategy across multiple regenerative medicine applications. Derived from adipose tissue, SVF exerts its effects primarily through paracrine, immunomodulatory, pro-angiogenic, and anti-fibrotic mechanisms rather than direct cell differentiation. Potential regenerative outcomes have been reported in bone, cartilage, scar modulation, and neural repair, highlighting a shared pro-regenerative cascade centered on early inflammation control and vascular support. Indeed, increasing evidence suggests that synergy with biomaterials and point-of-care one-step approaches further enhances SVF efficacy. Regarding the real clinical potential, however, transability is still limited due to heterogeneity in isolation methods, lack of standardization, and insufficient large-scale randomized controlled trials.
Perale et al. (Mon,) studied this question.